Abstract:Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was the most successful in having the longest temporal window of clinical use, showing a high degree of resiliency to SARS-CoV-2 evolution interrupted only by the appearance of the BA.2.86* variant of interest (VOI). This success undoubtedly reflects rational selection to target a highly conserved epitope in coronavirus Spike proteins. We review here the efficacy of sotrovimab against different SARS-CoV-2 variants in outpatients and inpatients, discussing both randomized controlled trials and real-world evidence. Although it could not be anticipated at the time of its development and introduction, sotrovimab's use in immunocompromised individuals who harbor large populations of variant viruses created the conditions for its eventual demise, as antibody selection and viral evolution led to its eventual withdrawal due to inefficacy against later variant lineages. Despite this, based on observational and real-world data, some authorities have continued to promote the use of sotrovimab, but the lack of binding to newer variants strongly argues for the futility of continued use. The story of sotrovimab highlights the power of modern biomedical science to generate novel therapeutics while also providing a cautionary tale for the need to devise strategies to minimize the emergence of resistance to antibody-based therapeutics.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the effectiveness of the monoclonal antibody sotrovimab against different SARS - CoV - 2 variants. Specifically, the paper reviews the efficacy of sotrovimab in outpatient and inpatient patients and discusses the results of randomized controlled trials and real - world evidence. In addition, the paper also explores the use of sotrovimab in immunocompromised individuals and how these use conditions have promoted the emergence of viral resistance, ultimately leading to a decline in the efficacy of sotrovimab. ### Key points: 1. **Background**: - Sotrovimab is a monoclonal antibody against a highly conserved epitope in the receptor - binding domain (RBD) of the SARS - CoV - 2 spike protein. - It was originally derived from the antibody S - 309 isolated from SARS - CoV recovered patients and has strong antiviral activity and a long half - life. 2. **Research objectives**: - To evaluate the effectiveness of sotrovimab against different SARS - CoV - 2 variants. - To discuss the performance of sotrovimab in clinical trials and practical applications. - To analyze the use of sotrovimab in immunocompromised individuals and its impact on viral resistance. 3. **Methods**: - Literature search: Articles published from December 1, 2019, to December 29, 2023, were retrieved through the PubMed, EMBASE, Cochrane Central, medRxiv, and bioRxiv databases. - Clinical trial data: Data from multiple randomized controlled trials (RCTs), including the COMET - ICE, MANTICO, and TICO trials, were analyzed. - Real - world evidence: Data from multiple observational and retrospective studies were analyzed. 4. **Results**: - **Outpatients**: - In the COMET - ICE trial, sotrovimab significantly reduced the hospitalization rate and mortality. - Other studies also showed that sotrovimab was effective in early treatment. - **Inpatients**: - In the TICO trial, sotrovimab failed to significantly reduce pulmonary complications or improve clinical recovery 90 days later. - **Viral evolution**: - Sotrovimab was highly effective before BA.2, but its efficacy significantly declined with the emergence of the BA.4/5 and BA.2.86* variants. - **Treatment - induced immune escape**: - Multiple case series reported resistance mutations that occurred after sotrovimab treatment, especially more common in immunocompromised patients. 5. **Discussion**: - The success of sotrovimab lies in its targeting of highly conserved epitopes, but this strategy also has limitations in the case of rapid viral evolution. - In immunocompromised patients, the use of sotrovimab may lead to the emergence of resistant viruses, which needs to be considered in future treatment strategies. - Future research should focus on how to reduce the emergence of resistance and improve the long - term effectiveness of monoclonal antibodies through combination therapies. ### Conclusion: Sotrovimab shows good results in early treatment, but its effectiveness gradually declines in the face of rapidly evolving viruses. This phenomenon suggests that when designing and using monoclonal antibodies, we need to comprehensively consider the evolutionary characteristics of the virus to reduce the emergence of resistance.

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Ultrapotent Bispecific Antibodies Neutralize Emerging SARS-CoV-2 Variants

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data

Comparison of the Neutralization Power of Sotrovimab Against SARS-CoV-2 Variants: Development of a Rapid Computational Method

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift